GSK launches $124-a-share takeover bid for cancer biotech Nuvalent

The offer is being made through Harmony Row Acquisition Co., a wholly owned GSK subsidiary, and targets all outstanding Class A and Class B shares of Nuvalent

Dr. GSK Velu recognised for lifetime contribution to healthcare innovation

The Trivitron Healthcare CMD and FICCI Tamil Nadu Chairman was honoured for advancing indigenous innovation and strengthening India's healthcare ecosystem

GSK bets big on oncology with $10.6 billion Nuvalent acquisition

Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio

GSK wins regulatory boost for once-monthly liver drug efimosfermin in MASH push

The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need

CHRI, PATH and GSK Cares launch AMR Safe Disposal Innovation Challenge 2026

The initiative is a significant step toward combating antimicrobial resistance (AMR) and reducing environmental contamination from antibiotic waste

GSK Pharma shareholders back Ronojit Biswas’ Board, CFO appointment via postal ballot

Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker

Samsung Biologics lands first US manufacturing facility with GSK acquisition

Samsung Biologics will continue supplying products previously manufactured at the site to GSK

GSK seeks European nod for promising Hepatitis B therapy

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk

GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly

The data highlights its RSV vaccine cuts hospitalizations in older adults